

Miodrag C. Ostojic, Eugenio Picano,
and Aleksandra Arandjelovic

For a rational use of stress tests and an appropriate interpretation of their results, it may be useful to adopt a pathogenetic classification, taking into account the diagnostic end point of the test. Tests inducing vasospasm (ergonovine infusion and hyperventilation) explore the functional component. Tests trying to unmask coronary stenosis (exercise, dipyridamole, adenosine, dobutamine, pacing) mostly explore the ceiling of coronary reserve as defined by organic factors (Fig. 5.1). Some of these stressors (such as exercise) may also induce variations in coronary tone which can be superimposed on the organic factors, thus blurring the correlation between coronary anatomy and test positivity.

5.1 Ischemia and Vasospasm

Since coronary vasospasm can coexist with any degree of coronary stenosis, the presence of angiographically normal coronary arteries does not rule out the possibility of vasospastic myocardial ischemia; on the other hand, a “significant” coronary stenosis at angiography does not automatically establish a cause–effect relationship between organic disease and myocardial ischemia. In the past 20 years, we have come to appreciate the fact that the endothelium serves not only as a nonthrombogenic diffusion barrier to the migration of substances into and out of the blood stream but also as the largest and most active paracrine organ in the body, producing potent vasoactive, anticoagulant, procoagulant, and fibrinolytic substances. Normal endothelium produces two vasoactive and platelet-active products, prostacyclin and nitric oxide (NO), which act in concert to inhibit platelet adhesion and aggregation and relax vascular smooth muscle [1]. Normal endothelium also opposes a variety of vasoconstrictive stimuli, including catecholamines, acetylcholine, and serotonin, and it enhances the vasorelaxant effects of dilators, such as adenosine nucleotides. In the presence of a dysfunctional endothelium, vasodilatory stimuli – such as adenosine or dipyridamole – may become less potent, and vasoconstrictive stimuli much more effective [1]. The mechanisms of coronary spasm are still unclear. No




Fig. 5.2 *Top:* endothelial and smooth muscle cells in coronary vessels in the presence of intact endothelium. Mediators such as serotonin, acetylcholine, and noradrenaline stimulate the corresponding receptors present on the endothelial surface, which induce smooth muscle cell relaxation and vasodilation via nitric oxide release. *Bottom:* when endothelium is damaged, the same mediators act directly on the corresponding receptors present on the smooth muscle membrane, causing vasoconstriction

increase in coronary tone, up to complete vasospasm, through α -sympathetic stimulation [3]. Dobutamine has a vasospastic and coronary vasoconstrictive effect mediated by α -adrenergic stimulation [4, 5]. Dipyridamole has no coronary constrictive effects per se; however, interruption of the test by aminophylline (which blocks adenosine receptors but also stimulates α -adrenoreceptors) can evoke coronary vasospasm in one-third of patients with variant angina [6]. Tests exploring organic fixed (without spasm) coronary stenosis can induce ischemia by means of two basic mechanisms: (a) an increase in oxygen demand, exceeding the fixed supply, and (b)

flow maldistribution due to inappropriate coronary arteriolar vasodilation triggered by a metabolic/pharmacological stimulus. The main pharmacodynamic actions of dobutamine and dipyridamole stresses are summarized in Tables 5.1 and 5.2, respectively. Dobutamine has complex dose-dependent effects on β_1 -, β_2 -, and α_1 -adrenoreceptors [7], whereas the principal targets of adenosine and dipyridamole are adenosine receptors, both A_1 and A_2 , present both in myocardium and in coronary vessels [8]. In particular, stimulation of A_2A receptors produces marked dilation of coronary resistance vessels, determining arteriolar vasodilation, whereas A_2B receptors mediate vasodilation in conductance vessels. Myocardial A_1 adenosine receptors mediate the negative chronotropic and dromotropic effects of adenosine and the direct algogenic effect. A_3 receptors are found on the surface of mast cells and may play a role in mediating bronchospasm and hypotension. Exogenous and endogenous adenosine may profoundly dilate coronary arterioles with minimal effect, if any, on systemic circulation, probably because A_2A receptors are more abundant in coronary arterioles than in any other vascular area [8]. A_1 and A_3 receptors also have a potential role in mediating preconditioning [8].

Adenosine is produced inside the cell via two pathways (Fig. 5.3), but it does not exert its effects until it leaves the intracellular environment and interacts with A_1 and A_2 adenosine receptors on the cell membrane [9]. As illustrated by the scheme in Fig. 5.3, dipyridamole acts by blocking the uptake and transport of adenosine into the cells, thereby resulting in a greater availability of adenosine at the receptor site.

Table 5.1 Pharmacodynamics of dobutamine

	Receptor populations		
	α_1	β_1	β_2
Myocardium	Increased inotropy	Increased chronotropy, increased inotropy	–
Vasculature	Vasoconstriction	–	Vasodilation

Table 5.2 Pharmacodynamics of adenosine and dipyridamole

	Receptor populations			
	A_1	A_2A	A_2B	A_3
Myocardium	Decreased chronotropy Decreased dromotropy Chest pain Preconditioning			
Vasculature		Coronary arteriolar vasodilation	Conductance vessel vasodilation	
Mast cells/ Mononuclear cells			Bronchoconstriction due to mast cell degranulation	Antiinflammatory effect




Fig. 5.3 Metabolism and mechanisms of action of adenosine in the coronary arteries. *ADO* adenosine, *AMP* adenosine monophosphate, *ADP* adenosine diphosphate, *ATP* adenosine triphosphate (Modified from Verani [9])

Both these mechanisms can provoke myocardial ischemia in the presence of a fixed reduction in coronary flow reserve due to organic factors (involving the epicardial coronary arteries and/or myocardium and/or microvasculature).

5.2 Increased Demand

This mechanism can be easily fitted into the familiar concept framework of ischemia as a supply–demand mismatch, deriving from an increase in oxygen requirements in the presence of a fixed reduction in coronary flow reserve. The different stresses can determine increases in demand through different mechanisms (Fig. 5.4).

In resting conditions, myocardial oxygen consumption is dependent mainly on heart rate, inotropic state, and left ventricular wall stress (which is proportional to the systolic blood pressure and left ventricular radius) [10]. Following dipyridamole or adenosine administration, due to their vasodilatory action, there are some decrease in the blood pressure with the compensatory increase of the sympathetic tone and consequent increase in contractility and heart rate [11].

During exercise, the increase in heart rate, blood pressure, and inotropic state accounts for the overall increase in myocardial oxygen consumption (Fig. 5.4) [12]. To a lesser degree, pacing and dobutamine also increase myocardial oxygen demand [13]. During pacing, the increase is mainly due to the increased heart rate. Dobutamine markedly increases contractility and heart rate (Fig. 5.4). Greater




Fig. 5.4 Major determinants of myocardial oxygen consumption in resting conditions (*left*) and during some stresses (*right*) commonly employed with echocardiography. The relative contributions of systolic blood pressure, heart rate, and inotropic state to myocardial oxygen demand are represented. During dipyridamole or adenosine stress, there is a mild increase in oxygen consumption, due to the increase in the heart rate and inotropic state, respectively. The rise in oxygen demand is even more marked during exercise, which causes an increased heart rate as well as increased inotropic state and systolic pressure (Redrawn and modified from Picano [10])

myocardial oxygen consumption due to heart rate increase occurs with the coadministration of atropine with dobutamine [14] and dipyridamole [15, 16].

5.3 Flow Maldistribution

In the presence of coronary atherosclerosis, appropriate arteriolar dilation can paradoxically exert detrimental effects on regional myocardial perfusion, causing overperfusion of myocardial layers or regions already well perfused in resting conditions at the expense of regions or layers with a precarious flow balance in resting conditions [17, 18].

In “vertical steal,” the anatomical requisite is the presence of an epicardial coronary artery stenosis, and the subepicardium “steals” blood from the subendocardial layers. The mechanism underlying vertical steal is a fall in poststenotic pressure secondary to the increase in flow across the stenosis [19]. From the hydraulic viewpoint, it is well known that even in the presence of a fixed anatomical stenosis, resistance is not fixed. After administration of dipyridamole, the arterioles dilate,

thereby increasing flow across the stenotic lesion. This increased flow may lead to a greater drop in pressure, the magnitude of which is related to the severity of the stenosis and to the increase in flow. In the presence of a coronary stenosis, the administration of a coronary vasodilator causes a fall in poststenotic pressure and therefore a critical fall in subendocardial perfusion pressure which in turn provokes a fall in absolute subendocardial flow, even with subepicardial overperfusion. In fact, the coronary autoregulation curve can be broken into two different curves, with the subendocardium more vulnerable than the subepicardium to lowering of coronary perfusion pressure. Regional thickening is closely related to subendocardial rather than transmural flow, and this explains the “paradox” of a regional asynergy, with ischemia in spite of regionally increased transmural flow. Because endocardial oxygen demands are greater than epicardial ones, the resistance vessels of the endocardium are more dilated than those of the subepicardium, ultimately resulting in selective subendocardial hypoperfusion.

“Horizontal steal” requires the presence of collateral circulation between two vascular beds (Fig. 5.5); the victim of the steal is the myocardium fed by the more stenotic vessel. The arteriolar vasodilatory reserve must be at least partially preserved in the donor vessel and abolished in the vessel receiving collateral flow [20, 21]. After vasodilation, the flow in the collateral circulation is reduced relative to resting conditions, since the arteriolar bed of the donor vessel “competes” with the arteriolar bed of the receiving vessel, whose vasodilatory reserve was already exhausted in resting conditions (Figs. 5.5 and 5.6).

The stresses provoking this flow maldistribution act through a “reverse Robin Hood effect” [22]; unlike the hero who stole from the rich to give to the poor [23, 24], they steal from the poor (myocardial regions or layers dependent on a critically stenosed coronary artery) and give to the rich (regions or layers already well nourished in resting conditions). The biochemical effector of this hemodynamic mechanism is the inappropriate accumulation of adenosine, which is the main physiological modulator of coronary arteriolar vasodilation. Inappropriate adenosine accumulation can be triggered either by a metabolic stimulus (such as exercise or pacing) or by a pharmacological one (such as exogenous adenosine or dipyridamole, which inhibits the cellular reuptake of endogenously produced adenosine) [25]. It is certainly difficult to quantify the relevance of flow maldistribution in inducing ischemia, but this mechanism is likely to play a key role in adenosine- or dipyridamole-induced ischemia and a relatively minor, although significant, role in exercise- or pacing-induced ischemia [23–26]. Theoretically, dobutamine might also induce a moderate degree of flow maldistribution by stimulating β -adrenergic receptors, which mediate coronary arteriolar vasodilation [27] (Fig. 5.7).

5.4 Exercise-Simulating Agents

Among stresses, a currently used differentiation is between “exercise-simulating agents,” such as dobutamine and vasodilator stressors, such as dipyridamole or adenosine. It is important to emphasize that none of the pharmacological stresses are




Fig. 5.5 Hydraulic model illustrating coronary horizontal steal. For this example, the right coronary artery (*RCA*) is the supply artery, with the vascular distribution of the severely stenotic left anterior descending (*LAD*) artery supplied by collaterals from the right coronary artery. Coronary steal following coronary arteriolar vasodilation refers to a decrease in absolute forward flow through collateral channels to the collateral-dependent vascular bed. With vasodilation of distal coronary arteriolar beds, there is a flow-related drop in pressure along the supply artery. Therefore, distal perfusion pressure to the collateral vessels falls since collateral flow depends primarily on the driving pressure gradient (between distal perfusion pressure of the supply and collateralized vascular bed) (Redrawn and modified from Picano [17])

“exercise simulating” in a strict sense. Only exercise offers complex information not only on coronary flow reserve but also on cardiac reserve and cardiovascular efficiency (i.e., how the coronary reserve is translated into external work). Coronary reserve and cardiovascular efficiency are codeterminants of exercise tolerance and therefore of the quality of life for the individual patient. No pharmacological stress can mimic the complex hemodynamic, neural, and hormonal adaptations triggered by exercise, nor can they offer information on cardiovascular efficiency. Exercise explores the entire physiological chain supporting external work: the psychological motivation, central and peripheral nervous system, lungs, myocardium, coronary circulation, peripheral blood circulation, and skeletal muscle down to cell respiration and mitochondrial oxygen utilization [28]. Of this chain, pharmacological stresses only test the “coronary” ring. From the echocardiographic viewpoint, the mechanical pattern of stress-induced function increase differs between exercise and pharmacological stresses – including dobutamine [29]. From the clinical viewpoint, changes in rate–pressure product can stratify disease severity with exercise, not with pharmacological stresses. Antianginal therapy affects pharmacological stress results – and especially dobutamine results (as discussed in more detail in Chap. 12)




Fig. 5.6 An example in which collaterals were supplied by the right coronary artery to the occluded left anterior descending artery. Two-dimensional echocardiographic frames, taken at end systole (*top*), and coronary angiographic images (*bottom*), obtained in basal conditions and after dipyridamole administration. After dipyridamole, the apex is dyskinetic; the coronary angiography shows almost total disappearance of the collateral vessels (*arrows*) (Modified from Picano [17])

in a manner largely unrelated to the effects of the same therapy on exercise. Finally, arrhythmias, heart rate, and blood pressure response enrich the diagnostic information obtainable with exercise stress testing, not with pharmacological testing. On the other hand, all stresses can be considered “exercise simulating” for the purpose of diagnosing coronary artery disease. Their mechanism of action is the extreme exaggeration of a biochemical and hemodynamic mechanism actually operating during exercise, such as adrenergic stimulation with dobutamine or adenosinergic stimulation with dipyridamole [23–25].

Last but not least, from a less physiological but more pragmatic point of view, all stresses should be considered exercise simulating since they induce ischemia with similar frequency, in the same region, and to a comparable degree as exercise. They also titrate the positive response, but the equivalent of the ischemic workload is the drug dose (the “pharmacological dose load”) sufficient to elicit ischemia.




Fig. 5.7 The biochemical pathways leading to inappropriate arteriolar vasodilation under different stresses

5.5 New Pharmacological Stresses

In the family of catecholaminic stresses, there was attempt with arbutamine. It was characterized by a potent β -agonist effect, with a stronger chronotropic and a milder inotropic action than dobutamine. It might be considered conceptually similar to a pacing test, since it stresses the myocardium mainly through an increase in heart rate [30]. It is not now in use anymore. For vasodilator stresses as well, the new A_{2A} agonist (regadenoson) with short half-life (2–3 min vs. up to 15 h for dipyridamole vs. 30 s for adenosine) which may be given in IV bolus (in contrast to dipyridamole and adenosine which have to be administered by IV infusion) was introduced [31–33]. The idea behind its development was to have less side effects with the drug which action is long enough to be administered as IV bolus (see Chap. 14).

5.6 The Atropine Role

Atropine is a naturally occurring antimuscarinic drug consisting of an alkaloid of the belladonna plants. During the time of the Roman Empire, the plant was frequently used to produce poison. This prompted Linnaeus to name the shrub *Atropa belladonna*, after Atropos, the eldest of the Three Fates, who cuts the thread of life. The name belladonna (i.e., “beautiful woman”) derives from the alleged use of this preparation by Italian women to dilate their pupils [34]. Atropine is the prototype of anti-muscarinic drugs, which inhibit the actions of acetylcholine on anatomical effectors innervated by postganglionic cholinergic nerves. The main effect of atropine on the heart is to induce tachycardia by blocking vagal effects on the M₂ receptors on the

sinoatrial nodal pacemaker. Atropine also enhances atrioventricular conduction, and for this reason it is usually given before pacing stress (see Chap. 15). Atropine-induced mydriasis may occasionally raise the intraocular pressure in patients with glaucoma, which is therefore a contraindication to atropine administration. Atropine also decreases the normal amplitude of bladder contraction, and severe prostatic disease is thus another contraindication to atropine administration. Finally, atropine reduces gastrointestinal tract motility and secretion and for this reason can be given before transesophageal stress. Administration of atropine on top of dobutamine [14] vasodilators [15, 16], or exercise [35, 36, 37] improves diagnostic sensitivity. Not surprisingly, however, the risk of resistant ischemia increases with atropine [38, 39], along with nonischemic side effects, including (as described in dobutamine plus atropine) atropine intoxication [40], consisting of restlessness, irritability, disorientation, hallucinations, or delirium, usually disappearing spontaneously over a few hours.

5.7 The Combined Stress Approach

The combined stress can be either dipyridamole–exercise or dipyridamole–dobutamine. There are also attempts and reports on combining mental stress test and exercise [41, 42].

Dipyridamole causes only a trivial increase in myocardial oxygen demand, provoking ischemia mainly through flow maldistribution phenomena triggered by endogenous adenosine accumulation. The flow increase achieved by a high dipyridamole dose lasts for a relatively long time, remaining at plateau for about 30 min and, therefore, representing an ideal “flow maldistribution” background over which another stress can be superimposed. It has previously been shown that dipyridamole does not block the hemodynamic response of exercise [43] or dobutamine [44] and that it potentiates the ischemic potential of both exercise and dobutamine. The underlying hypothesis is that a stepwise increment of myocardial oxygen consumption – unable per se to elicit ischemia in the presence of mild coronary artery disease – might reach the critical threshold when the ischemic ceiling is lowered by concomitant flow maldistribution triggered by dipyridamole infusion [43] (Fig. 5.8). The clinical fact is that the combined stress test can detect anatomically milder forms of coronary disease missed by either test used separately [43–45].

5.8 Vasodilatory Power and the Hierarchy of Testing

Each of the prototype stresses for the detection of coronary artery disease can induce ischemia through either one of the three main pathophysiological pathways: spasm, “steal effect” (also named flow maldistribution), and increased oxygen demand.

No stress is 100 % “pure,” since adenosine and dipyridamole also slightly increase heart rate and exercise and dobutamine also induce a certain (mild) degree of flow maldistribution. Both families of stresses are more or less equally effective as ischemic stressors in the presence of significant coronary artery disease (Fig. 5.9).




Fig. 5.8 Dipyridamole sensitization of the ischemic potential of exercise. Coronary stenosis (*thick arrow*) may permanently although not severely lower the maximal flow availability (coronary reserve), so that the myocardial ischemic threshold is not reached with an “ordinary” exercise stress test. With dipyridamole premedication (*thin arrow*), the hemodynamic response to exercise is not prevented (normal stepwise increase in workload), but the maximal flow availability is significantly lowered for the occurrence of flow maldistribution phenomena (From Picano et al [43] with permission)

For a given ischemic diagnostic marker (for instance, regional wall motion abnormalities with stress echocardiography), sensitivity is higher for tests combining the two pathways (such as dipyridamole–exercise, dipyridamole–dobutamine, or dipyridamole–atropine) when compared with tests based on one pathway (dipyridamole or dobutamine or exercise) alone. Different stressors are not competitors but allies as there are some comorbidities which are contraindications for particular stressor (regarding atropine mentioned above) [46]. Relative contraindications for dobutamine are hypertension and arrhythmias. Adenosine and dipyridamole are not recommended in bronchial asthma, sinoatrial and atrioventricular blocks, as well as patients taking dipyridamole. Common contraindications for all pharmacological stressors are pregnancy (or attempt to get pregnant) and breastfeeding. Some people due to skeletomuscular problems and/or poor motivation cannot exercise. Therefore in order to diagnose coronary artery disease as well as to conduct efficient follow-up post-myocardial revascularization, each stress-echo lab should be familiar with different stressors. Those stressors may be used like fishermen use nets to catch large-, medium-, or small-sized fish, i.e., to detect mild, moderate, and severe coronary




Fig. 5.9 The hierarchy of test sensitivity for the diagnosis of coronary artery disease. The sensitivity is highest for tests combining the two main mechanisms of increased oxygen consumption and steal phenomena. *Dip-Ex* dipyridamole–exercise, *Dip* dipyridamole, *Ado* adenosine, *Dob* dobutamine, *HG* handgrip, *MS* mental stress, *PAC* pacing

heart disease (“the fisherman approach”). As presented in Fig 5.10, dipyridamole or adenosine alone will detect the most severe disease (3 – vessel disease, left main, the sickest of the sick – troublemakers in the relatively short run) and, at the other end of the spectrum, combined dipyridamole with dobutamine or exercise will detect the mild forms (milder single-vessel disease) [47].

The relevance of the steal effect is also directly mirrored by the stress capacity to recruit coronary flow reserve. Adenosinergic stresses are ideally suited for this, since – unlike dobutamine or exercise associated with a threefold flow increase – they determine a fivefold increase in coronary blood flow with a full recruitment of pharmacological flow reserve [48]. The greater the vasodilation, the higher the potential for inappropriate steal phenomena in the presence of coronary artery disease. In recent years, the two different sides of the coin of the stress test, vasodilatory and ischemic stress, merged in the dual imaging of coronary flow reserve and wall motion during vasodilatory stress echocardiography [50, 51, 52]. Triple imaging, i.e., perfusion in addition to wall motion abnormalities and coronary flow reserve with dipyridamole contrast echocardiography, has been described [52].

5.9 Different Pathophysiological Approaches in the Stress-Echo Lab

The use of stress to increase myocardial oxygen demand in order to provoke ischemia is like the classic straddle method in the high jump: it is conceptually familiar to everybody (everyone has tried it at least once) and it is pushed forward by the




Fig. 5.10 The Fisherman approach: No coronary artery disease (CAD) up to very severe CAD are presented as small fish (*green*) up to the biggest ones (*purple*), respectively. The nets with different size holes from the biggest up to the smallest, i.e., dipyridamole (*Dip*), dobutamine (*Dob*), exercise (*Ex*), Dip–Dob, and Dip–Ex are presented. The “size of the holes” for the each stress was determined at the optimal cut-off between sensitivity and specificity where coronary angiography was used as the gold standard for the each particular test in the same set of patients. It may be appreciated that cut-off for Ex was exactly 50 % stenosis (as postulated in animal experiments), for Dip, Dob, Dip–Dob, and Dip–Ex those cut-offs were 58 %, 52 %, 39 %, and 31 %, respectively. Therefore if the interest is just to catch a big fish, Dip will be used

force of tradition. The steal effect is like the “Fosbury flop”: it is more recent, may appear counterintuitive, but works at least as well as the straddle method. As a young high jumper in the early 1960s, Dick Fosbury had trouble mastering the standard technique, called the straddle, so he began doing the high jump by approaching the bar with his back to it instead, doing a modified scissor kick and going over the bar backward and horizontal to the ground. As goofy as it looked, it worked. Similarly, as strange as it may look within the supply–demand mismatch framework, the concept of inducing ischemia through a vasodilator instead of by increasing myocardial oxygen demand has worked. Fosbury caused a sensation when he won the gold medal in the 1968 Olympics. The Fosbury flop has since become a standard technique for high jumpers – whether Olympic champions pushing forward the limits of the specialty or kids in gym class at elementary school. Thirty years after the initial proposal in 1985, vasodilatory stress echocardiography is the convenient option for primary care stress echocardiographers, who will benefit from a stress that pollutes the image quality very little, reducing the problems of interpretation. It is also a good option for stress echocardiographers with top-level expertise

and technology, since it allows one to combine wall motion and coronary flow imaging in the same stress [49, 50]. Dual imaging has been recommended by European guidelines as the state-of-the-art approach along with pharmacological stress echocardiography [51]. Recently from the experience of nuclear cardiology imaging in detecting coronary artery disease by using adenosine and synthetic adenosine A2A receptor agonist (regadenoson), serious complications (acute myocardial infarction, cardiac arrest, and death) were observed in patients having signs and symptoms of unstable angina [53]. Although that number is very small having in mind that millions of tests have been done, it prompted FDA to issue a warning on November 20, 2013, advising a special caution in using them and whenever possible switching to dipyridamole or dobutamine. In stress-echo community, it has been very well emphasized from the very beginning by conducting international multi-center registries that provoking myocardial ischemia is like playing with fire, i.e., test is indicated only when the benefit of establishing diagnosis outweighs the risk of test, whatever it is [40, 54].

5.10 Clinical Guidelines

For functional imaging, exercise, dobutamine, and vasodilators have similar diagnostic accuracy, when appropriately high doses of drugs are used. For combined perfusion and functional imaging, vasodilators appear to be more user-friendly. There is no complication free stress-echo test, so it should be used when the benefit of establishing diagnosis outweighs the risk in each individual patient [51, 55–57]. Being an expert not just as stress echocardiographer, but as cardiologist in the field of coronary artery disease is the prerequisite for successful taking care of the patients.

Table of Contents Video Companion

See also in the section Selected presentations: Pharmacologic and myocardial effects of adenosine and dipyridamole
Springer Extra Materials available at <http://extras.springer.com/2015/978-3-319-20957-9>

References

1. Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. *Arterioscler Thromb Vasc Biol* 23:168–175
2. Nedeljkovic M, Ostojic M, Beleslin B et al (2001) The efficiency of ergonovine echocardiography in detection of angiographically assessed coronary vasospasm. *Am J Cardiol* 88:1183–1187
3. Feigl EO (1987) The paradox of adrenergic coronary vasoconstriction. *Circulation* 76:737–745

4. Kawano H, Fujii H, Motoyama T et al (2000) Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography. *Am J Cardiol* 85:26–30
5. Roffi M, Meier B, Allemann Y (2000) Angiographic documented coronary arterial spasm in absence of critical coronary artery stenoses in a patient with variant angina episodes during exercise and dobutamine stress echocardiography. *Heart* 83, E4
6. Picano E, Lattanzi F, Masini M et al (1988) Aminophylline termination of dipyridamole stress as a trigger of coronary vasospasm in variant angina. *Am J Cardiol* 62:694–697
7. Ruffolo RR Jr, Spradlin TA, Pollock GD et al (1981) Alpha- and -adrenergic effects of the stereoisomers of dobutamine. *J Pharmacol Exp Ther* 219:447–452
8. Fredholm BB, Abbracchio MP, Burnstock G et al (1994) Nomenclature and classification of purinoceptors. *Pharmacol Rev* 46:143–156
9. Verani MS (1991) Adenosine thallium 201 myocardial perfusion scintigraphy. *Am Heart J* 122:269–278
10. Picano E (1992) Stress echocardiography: from pathophysiologic toy to diagnostic tool. Point of view. *Circulation* 85:1604–1612
11. Picano E, Simonetti I, Carpeggiani C et al (1989) Regional and global biventricular function during dipyridamole stress testing. *Am J Cardiol* 63:429–432
12. Beleslin BD, Ostojic M, Stepanovic J et al (1994) Stress echocardiography in the detection of myocardial ischemia. Head-to-head comparison of exercise, dobutamine, and dipyridamole tests. *Circulation* 90:1168–1176
13. Shimoni S, Goland S, Livshitz S et al (2010) Accuracy and long-term prognostic value of pacing stress echocardiography compared with dipyridamole t1201 emission computed tomography in patients with a permanent pacemaker and known or suspected coronary artery disease. *Cardiology* 116:229–236
14. McNeill AJ, Fioretti PM, el-Said SM et al (1992) Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dobutamine stress echocardiography. *Am J Cardiol* 70:41–46
15. Picano E, Pingitore A, Conti U et al (1993) Enhanced sensitivity for detection of coronary artery disease by addition of atropine to dipyridamole echocardiography. *Eur Heart J* 14:1216–1222
16. Nedeljkovic IP, Ostojic M, Beleslin B et al (2006) Comparison of exercise, dobutamine-atropine and dipyridamole-atropine stress echocardiography in detecting coronary artery disease. *Cardiovasc Ultrasound* 4:22
17. Picano E (1989) Dipyridamole-echocardiography test: historical background and physiologic basis. *Eur Heart J* 10:365–376
18. Picano E (2002) Dipyridamole in myocardial ischemia: good Samaritan or Terminator? *Int J Cardiol* 83:215–216
19. Bove AA, Santamore WP, Carey RA (1983) Reduced myocardial blood flow resulting from dynamic changes in coronary artery stenosis. *Int J Cardiol* 4:301–317
20. Guyton RA, McClenathan JH, Newman GE et al (1977) Significance of subendocardial S-T segment elevation caused by coronary stenosis in the dog. Epicardial S-T segment depression, local ischemia and subsequent necrosis. *Am J Cardiol* 40:373–380
21. Demer L, Gould KL, Kirkeeide R (1988) Assessing stenosis severity: coronary flow reserve, collateral function, quantitative coronary arteriography, positron imaging, and digital subtraction angiography. A review and analysis. *Prog Cardiovasc Dis* 30:307–322
22. Picano E, Lattanzi F (1991) Dipyridamole echocardiography. A new diagnostic window on coronary artery disease. *Circulation* 83:III19–III26
23. Crea F, Pupita G, Galassi AR et al (1989) Effect of theophylline on exercise-induced myocardial ischaemia. *Lancet* 1:683–686
24. Emdin M, Picano E, Lattanzi F et al (1989) Improved exercise capacity with acute aminophylline administration in patients with syndrome X. *J Am Coll Cardiol* 14:1450–1453
25. Cannon RO 3rd (1989) Aminophylline for angina: the “Robin Hood” effect? *J Am Coll Cardiol* 14:1454–1455
26. Picano E, Pogliani M, Lattanzi F et al (1989) Exercise capacity after acute aminophylline administration in angina pectoris. *Am J Cardiol* 63:14–16

27. Waltier DC, Ziwołoski M, Gross FJ et al (1981) Redistribution of myocardial blood flow distal to a dynamic coronary artery stenosis by sympathomimetic amines. *Am J Cardiol* 48:269–279
28. Varga A, Preda I (1997) Pharmacological stress echocardiography for exercise independent assessment of anti-ischaemic therapy. *Eur Heart J* 18:180–181
29. Carstensen S, Ali SM, Stensgaard-Hansen FV et al (1995) Dobutamine-atropine stress echocardiography in asymptomatic healthy individuals. The relativity of stress-induced hyperkinesia. *Circulation* 92:3453–3463
30. Hammond HK, McKirnan D (1994) Effects of dobutamine and arbutamine on regional myocardial function in a porcine model of myocardial ischemia. *J Am Coll Cardiol* 23:475–482
31. Glover DK, Ruiz M, Yang JY et al (1996) Pharmacological stress thallium scintigraphy with 2-cyclohexylmethylidenehydrazino adenosine (WRC-0470). A novel, short-acting adenosine A2A receptor agonist. *Circulation* 94:1726–1732
32. Cerqueira MD (2004) The future of pharmacologic stress: selective A2A adenosine receptor agonists. *Am J Cardiol* 94(2A):33D–40D; discussion 40D–42D
33. Zoghbi GJ, Iskandrian AE (2012) Selective adenosine agonists and myocardial perfusion imaging. *J Nucl Cardiol* 19:126–141
34. Brown JH (1992) Atropine, scopolamine and related antimuscarinic drugs. In: Goodman A, Gilman G (eds) *The pharmacologic basis of therapeutics*, vol 1, 8th edn. McGraw Hill, New York, pp 150–165
35. Miyazono Y, Kisanuki A, Toyonaga K et al (1998) Usefulness of adenosine triphosphate atropine stress echocardiography for detecting coronary artery stenosis. *Am J Cardiol* 82:290–294
36. Attenhofer CH, Pellikka PA, Roger VL et al (2000) Impact of atropine injection on heart rate response during treadmill exercise echocardiography: a double-blind randomized pilot study. *Echocardiography* 17:221–227
37. Banerjee S, Yalamanchili VS, Abdul-Baki T et al (2002) Use of atropine to maintain higher heart rate after exercise during treadmill stress echocardiography. *J Am Soc Echocardiogr* 15:43–45
38. Nedeljkovic MA, Ostojic M, Beleslin B et al (2001) Dipyridamole-atropine-induced myocardial infarction in a patient with patent epicardial coronary arteries. *Herz* 26:485–488
39. Erdogan O, Altun A, Akdemir O et al (2001) Unexpected occurrence of ST segment elevation during administration of intravenous atropine. *Cardiovasc Drugs Ther* 15:367–368
40. Mathias W Jr, Arruda A, Santos FC et al (1999) Safety of dobutamine-atropine stress echocardiography: a prospective experience of 4,033 consecutive studies. *J Am Soc Echocardiogr* 12:785–791
41. Hunziker PR, Gradel C, Muller-Brand J et al (1998) Improved myocardial ischemia detection by combined physical and mental stress testing. *Am J Cardiol* 82:109–113
42. Stepanovic J, Ostojic M, Beleslin B et al (2012) Mental stress-induced ischemia in patients with coronary artery disease: echocardiographic characteristics and relation to exercise-induced ischemia. *Psychosom Med* 74:766–772
43. Picano E, Lattanzi F, Masini M et al (1988) Usefulness of the dipyridamole-exercise echocardiography test for diagnosis of coronary artery disease. *Am J Cardiol* 62:67–70
44. Ostojic M, Picano E, Beleslin B et al (1994) Dipyridamole-dobutamine echocardiography: a novel test for the detection of milder forms of coronary artery disease. *J Am Coll Cardiol* 23:1115–1122
45. Moir S, Haluska BA, Jenkins C et al (2004) Incremental benefit of myocardial contrast to combined dipyridamole-exercise stress echocardiography for the assessment of coronary artery disease. *Circulation* 110:1108–1113
46. Ostojic M, Picano E, Beleslin B et al (1995) Dipyridamole and dobutamine: competitors or allies in pharmacological stress echocardiography. *Eur Heart J* 16(Suppl I):26–30
47. Beleslin B, Ostojic M, Djordjevic-Dikic A et al (1999) Integrated evaluation of relation between coronary lesion features and stress echocardiography results: The importance of coronary lesion morphology. *J Am Coll Cardiol* 33:717–727
48. Iskandrian AS, Verani MS, Heo J (1994) Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease. *J Nucl Cardiol* 1:94–111

49. Rigo F, Richieri M, Pasanisi E et al (2003) Usefulness of coronary flow reserve over regional wall motion when added to dual-imaging dipyridamole echocardiography. *Am J Cardiol* 91:269–273
50. Rigo F, Sicari R, Gherardi S et al (2008) The additive prognostic value of wall motion abnormalities and coronary flow reserve during dipyridamole stress echo. *Eur Heart J* 29:79–88
51. Sicari R, Nihoyannopoulos P, Evangelista A, on behalf of the European Association of Echocardiography, et al (2008) Stress echocardiography expert consensus statement: European Association of Echocardiography (EAE) (a registered branch of the ESC). *Eur J Echocardiogr* 9:415–437
52. Gaibazzi N, Rigo F, Lorenzoni V et al (2013) Comparative prediction of cardiac events by wall motion, wall motion plus coronary flow reserve, or myocardial perfusion analysis: a multi-center study of contrast stress echocardiography. *JACC Cardiovasc Imaging* 6:1–12
53. Editorial (Anonymous) (2014) FDA Issues Warning on Regadenoson and Adenosine. *J Nucl Med* 55:12N
54. Picano E, Marini C, Pirelli S et al (1992) Safety of intravenous high-dose dipyridamole echocardiography. *Am J Cardiol* 70:252–258
55. European Association for Percutaneous Cardiovascular Interventions, Wijns W, Kolh P, Danchin N et al (2010) Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 20:2501–2555
56. Harb SC, Cook T, Jaber WA et al (2012) Exercise testing in asymptomatic patients after revascularization: are outcomes altered? *Arch Intern Med* 11:854–861
57. Harb SC, Marwick TH (2014) Prognostic value of stress imaging after revascularization: a systematic review of stress echocardiography and stress nuclear imaging. *Am Heart J* 167:77–85